May 30, 2016
A domestic PIII trial of the cancer peptide vaccine ITK-1 for the treatment of castration-resistant prostate cancer is expected to be completed in FY2017, with an application for marketing authorization anticipated in FY2018. ITK-1 is a tailor-made cancer peptide vaccine...read more